Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HK1 | P19367 | 1/20 | 0.40 |
| ▸ | HK2 | P52789 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13156516 | 1.00 | L3MBTL1 (0.50) | L3MBTL1ALOX5CA1CA2CA4 | |
| SCHEMBL13156519 | 0.87 | NPC1 (0.52) | LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL3089032 | 0.87 | NPC1 (0.52) | LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL3100194 | 0.86 | L3MBTL1 (0.47) | L3MBTL1ALOX5CA1CA2CA4 | |
| SCHEMBL13156476 | 0.86 | L3MBTL1 (0.47) | L3MBTL1ALOX5CA1CA2CA4 | |
| SCHEMBL31291527 | 0.86 | L3MBTL1 (0.56) | L3MBTL1ALOX5TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL13181726 | 0.83 | L3MBTL1 (0.44) | L3MBTL1ALOX5CA1CA2CA4 | |
| SCHEMBL457103 | 0.80 | L3MBTL1 (0.50) | L3MBTL1ALOX5CA1CA2TAS1R3 | |
| SCHEMBL10024168 | 0.80 | L3MBTL1 (0.50) | L3MBTL1ALOX5TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL13139940 | 0.80 | TAS1R3 (0.63) | L3MBTL1TAS1R3TAS1R1TAS1R2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799934-B2 | Intermediates (synthons) in the synthesis of pharmaceuticals such as oseltamivir and other products; treating the arizidine with the nucleophile in the presence of a biaryl phosphoric acid catalyst | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090030212-A1 | Enantioselective ring-opening of aziridines | UNIVERSITY OF SOUTH FLORIDA OF TAMPA | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030212-A1 | Enantioselective ring-opening of aziridines | AZI2, ITPA, ADORA2A | L3MBTL1 4868/4885ALOX5 1209/4885CA1 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.